Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read More
FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Sunshine Lake Pharma, Lannett Company, and its wholly owned subsidiary Lanexa Biologics have achieved a significant milestone in diabetes care…
Read More
The Shifting Landscape of Gene Therapy: Non-Viral Approaches Emerge as Promising Alternatives
Cell and gene therapies (CGTs) have long been heralded for their potential to revolutionize the treatment of complex and previously…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
The Joint Clinical Assessment: Navigating Procedural and Methodological Hurdles in EU Drug Evaluation
The advent of the Joint Clinical Assessment (JCA) process in the European Union, designed to harmonize the clinical evaluation of…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases
In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…
Read MoreYOU MAY HAVE MISSED
